Progenika Biopharma S.A., a pioneer in the field of Personalized Medicine, since its foundation in 2000, has been constantly innovating using the latest technologies.
Our main objective is the development, production and commercialization of tools for the diagnosis and prognosis of diseases and for predicting response to drug treatment.
Progenika has made substantial investments in the development of our own technologies for the production of DNA based in diagnostic tools and has become a global leader in the area of pharmacogenetics.
Progenika appreciates the crucial importance of its human resources to its ongoing success. Currently, over 130 highly qualified professionals work at the company headquarters in Bilbao (Spain) and Cambridge (MA, USA), including over 85 scientists from the pharmaceutical and biotechnological industries, as well as from prestigious international research centres, being their efforts the ones that result in a continual development of innovative products based on DNAchip technology. Progenika DNAchips provide medical specialists and their patients with the tools that will improve the quality of healthcare in the 21st century.
With the collaboration of:
